Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics' Q2 Revenues Nearly Triple

NEW YORK (GenomeWeb News) – Response Genetics today reported that its second-quarter revenues nearly tripled, due to sales of the firm's ResponseDx genetic tests.

The Los Angeles-based firm reported total revenues of $5.6 million for the three-month period ended June 30, compared to $1.9 million for the second quarter of 2009. It said that sales of its ResponseDx tests increased 687 percent to $3.5 million for the quarter from $446,000 for Q2 2009.

Response Genetics also trimmed its net loss to $425,038, or $.02 per share, from $2.4 million, or $.19 per share.

Its R&D spending declined to $388,046 from $433,107, while its SG&A spending increased sharply to 43.2 million from $2.2 million. The increase in SG&A was due to an expansion of the firm's sales force, legal expenses associated with ongoing proxy activities, and personnel recruiting costs.

Response Genetics finished the quarter with $6.6 million in cash and cash equivalents.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.